A fascinating trend is emerging in the startup ecosystem: successful biotechnology entrepreneurs are launching dedicated artificial intelligence companies rather than integrating AI into their existing biotech ventures. The latest example comes from Ben Lamm’s decision to partner with George Church on Astromech, raising $30 million for AI development while continuing to run Colossal Biosciences separately.

This strategic separation reflects several essential market dynamics. First, AI companies often achieve higher valuations than biotechnology ventures due to faster development cycles and more scalable business models. Software-based AI tools can be deployed globally without the regulatory hurdles that constrain biotech products. Investors increasingly view AI as a safer, more liquid investment category.

Second, the skill sets required for AI development differ significantly from traditional biotechnology operations. Building machine learning models requires different talent, infrastructure, and management approaches than conducting laboratory research or clinical trials. Separate companies allow entrepreneurs to optimize each organization for its specific requirements.

Third, Astromech’s stealth-mode approach suggests they’re building platform technologies that could eventually serve multiple industries, not just biotechnology. By creating an independent AI company, Lamm and Church can pursue opportunities beyond their initial biotech focus without diluting Colossal’s mission.

The funding mechanics also favor this approach. AI investors and biotech investors often come from different backgrounds with distinct risk preferences and timeline expectations. Separate companies allow entrepreneurs to access both investor communities without forcing either group to evaluate unfamiliar business models.

However, managing multiple companies simultaneously creates significant challenges. Entrepreneurs must divide their attention between ventures, manage potential conflicts of interest, and maintain distinct corporate cultures. Success requires exceptional organizational skills and strong management teams.

The trend extends beyond Lamm and Church. Other biotech veterans are launching AI-focused ventures, recognizing that artificial intelligence represents both a complement to and potential replacement for traditional biotechnology approaches. Some are building AI tools to accelerate drug discovery, others are developing platforms for genomics research, and still others are creating diagnostic systems.

For the biotechnology industry, this trend signals maturation. As the field becomes more sophisticated, entrepreneurs are recognizing opportunities to specialize rather than trying to build vertically integrated companies that handle everything from AI development to clinical trials.